I'm hoping here that HN isn't going to be too taken in by a good PR strategy from the biotechs who are supporting the clinical trials here (Seattle Genetics and

I'm hoping here that HN isn't going to be too taken in by a good PR strategy from the biotechs who are supporting the clinical trials here (Seattle Genetics and Genmab - see here: https://www.clinicaltrials.gov/ct2/show/NCT03485209 https://www.clinicaltrials.gov/ct2/show/NCT03485209) I mean, it's interesting data, and any step forwards in treating cancers (especially solid tumours) is great... but this isn't especially novel. Toxin-bearing antibodies like this have been worked on now for years; indeed, there are examples which have successfully made it all the way through large phase III trials and onto the market, which takes many years. e.g. https://www.medicines.org.uk/emc/product/2859 https://www.medicines.org.uk/emc/product/2859 and https://www.medicines.org.uk/emc/product/9537/smpc https://www.medicines.org.uk/emc/product/9537/smpc